Objective To assess the clinical value of transartcrial infusion chemotherapy combined with high intensity focused ultrasound ( HIFSJ )for the treatment of pancreatic carcinomas. Methods A total of 64 patients with inoperable pancreatic carcinomas were randomly divided ink) study group( n =32 ) and control group (n = 32 ). Transarterial infusion chemotherapy combined with H1FU was employed in patients of study group, while simple transarterial infusion chemotherapy was conducted in patients of control group. The effective rate, the clinical benefit rate (CRR), the occurrence of side effect and the survival time of the two groups were recorded. The results were compared between the two groups. Results The effective rate ( PR + MR), the median survival time and the one-year survival rate of the study group were 55.56%, 13.0 mouths and 68,75% respectively, while The effective rate ( PR + MR ), the median survival time and the one-year survival rate of the control group were 28.57%, 9.0 mouths and 43.75% respectively. Both the effective rate and the one year survival rale of the study group were significantly higher than those of the control group (P < 0.05 ). Conclusion Compared with pure transarterial infusion chemotherapy, transarterial infusion chemotherapy combined with HIFU can significantly improve the short-term efficacy and increase the one-year survival rate for patients with advanced pancreatic carcinomas.%目的 评价动脉灌注化疗联合高强度聚焦超声治疗胰腺癌的临床价值.方法 将64例不能手术切除的胰腺癌患者随机分成2组,研究组32例采用动脉灌注化疗联合高强度聚焦超声方案;对照组32例采用动脉灌注化疗方案.观察两组方案的有效率、临床收益率、不良反应和生存期.结果 两组近期有效率(PR + MR)分别为55.56%和28.57%(P ＜ 0.05),中位生存期分别为13个月和9个月,1年生存率分别为68.75%和43.75%(P ＜ 0.05).结论 经动脉灌注化疗联合高强度聚焦超声较单纯动脉灌注化疗治疗胰腺癌可明显提高近期有效率和患者的1年生存率.
展开▼
